特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
959710

ガレトスマブ (REGN2477):新薬の洞察と市場予測 (2030年)

GARETOSMAB (REGN2477)- Emerging Drug Insight and Market Forecast - 2030

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 50 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.45円
ガレトスマブ (REGN2477):新薬の洞察と市場予測 (2030年)
出版日: 2020年09月08日
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ガレトスマブ (garetosmab:REGN2477) は、VelocImmune由来の完全ヒトモノクローナル抗体で、FOP患者の異所性骨 (HO) の発生に関与するアクチビンAと結合して中和する作用があります。2017年には米国FDA (連邦食品医薬品局) により、FOP患者のHO予防向けのファストトラックの指定を受けています。また、米国とEU圏内で希少疾病用医薬品の指定を受けています。ガレトスマブ現在は治験中であり、その安全性と有効性は規制当局によって評価されていません。

当レポートでは、進行性骨化性線維異形成症 (FOP) の治療薬であるガレトスマブ (REGN2477) の市場構造・動向について分析し、製品の概要 (用法・容量、作用機序など) や関連規制、製品開発・治験の進行状況、主要7ヶ国 (米国、欧州5ヶ国 (ドイツ、フランス、イタリア、スペイン、英国)、日本) の市場規模の動向見通し (2020~2030年)、市場の競争状態・SWOT分析、他の治療薬との競合状態、資本取引の動き、今後の市場成長の可能性などを調査・考察しております。

目次

第1章 医薬品の概要

  • 製品の詳細情報
  • 作用機序
  • 用法・用量
  • 研究開発 (R&D) 活動
    • 臨床開発
    • 安全性・有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国 (7MM) の市場分析
  • 米国市場
  • ドイツ市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場
  • 日本市場

第3章 SWOT分析

第4章 アナリストの見解

第5章 市場参入企業

第6章 その他の新たな治療法

第7章 付録

第8章 レポート購入オプション

図表

List of Tables

  • Table 1 GARETOSMAB (REGN2477), Description
  • Table 2 GARETOSMAB (REGN2477), Clinical Trial Description
  • Table 3 GARETOSMAB (REGN2477), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of GARETOSMAB (REGN2477)
  • Figure 2 Patent Details, GARETOSMAB (REGN2477)
  • Figure 3 GARETOSMAB (REGN2477), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 GARETOSMAB (REGN2477), US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 GARETOSMAB (REGN2477), EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 GARETOSMAB (REGN2477), Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0061

"GARETOSMAB (REGN2477)- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Fibrodysplasia ossificans progressiva (FOP) in 7 Major Markets. A detailed picture of the GARETOSMAB (REGN2477) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

Regeneron has been engaged in FOP research for over two decades and helped to provide fundamental insights in the biology and natural history of the disease. Regeneron scientists discovered that Activin A plays a key role in FOP by driving HO, the main pathology of FOP. Garetosmab is a VelocImmune-derived fully-human monoclonal antibody that binds and neutralizes Activin A, which is involved in the development of heterotopic bone in people with FOP. Garetosmab is currently being studied in adults with FOP. In 2017, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for garetosmab for the prevention of HO in patients with FOP. In the U.S. and European Union (EU), garetosmab has been granted Orphan Designation. Garetosmab is currently under clinical development, and its safety and efficacy have not been evaluated by any regulatory authority

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around GARETOSMAB (REGN2477).
  • The report contains forecasted sales for GARETOSMAB (REGN2477) till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Fibrodysplasia ossificans progressiva (FOP).
  • The report also features the SWOT analysis with analyst insights and key findings of GARETOSMAB (REGN2477).

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

GARETOSMAB (REGN2477) Analytical Perspective by DelveInsight

  • In-depth GARETOSMAB (REGN2477) Market Assessment

This report provides a detailed market assessment of GARETOSMAB (REGN2477) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • GARETOSMAB (REGN2477) Clinical Assessment

The report provides the clinical trials information of GARETOSMAB (REGN2477) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Fibrodysplasia ossificans progressiva (FOP) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence GARETOSMAB (REGN2477) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Fibrodysplasia ossificans progressiva (FOP) are giving market competition to GARETOSMAB (REGN2477) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of GARETOSMAB (REGN2477).
  • Our in-depth analysis of the forecasted sales data of GARETOSMAB (REGN2477) from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the GARETOSMAB (REGN2477).

Key Questions:

  • Which company is developing GARETOSMAB (REGN2477) along with the phase of the clinical study?
  • What is the technology utilized in the development of GARETOSMAB (REGN2477)?
  • What is the product type, route of administration and mechanism of action of GARETOSMAB (REGN2477)?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the GARETOSMAB (REGN2477) development?
  • What are the key designations that have been granted to GARETOSMAB (REGN2477)?
  • What is the forecasted market scenario of GARETOSMAB (REGN2477)?
  • What is the history of GARETOSMAB (REGN2477) and what is its future?
  • What is the forecasted sales of GARETOSMAB (REGN2477) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to GARETOSMAB (REGN2477)?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.